
1. Technology overview
Artrya Ltd (ACN 624 005 741) is an Australian company at 1257 Hay Street, West Perth, developing AI software for cardiac CT. Its privacy policy states that it is bound by the Australian Privacy Principles under the Privacy Act 1988.
Salix is web-based software that trained clinicians use to view and analyze cardiac CT data. It helps determine the presence and extent of coronary plaque and stenosis and quantifies calcium (calcium scoring) in patients who had coronary CT angiography. It works with CT images from any scanner and is positioned as an adjunct to clinician judgment. Salix Coronary Anatomy is on the Australian Register of Therapeutic Goods.
2. Highlighted features & specifications
- Plaque analysis: determines presence and extent of coronary plaque.
- Stenosis assessment: analyzes narrowing of coronary arteries on CCTA.
- Calcium scoring: quantifies coronary calcium from cardiac CT.
- Scanner-agnostic: accepts CT images from any scanner.
- Web-based viewer: trained clinicians open and analyze studies in a browser.
- Clinician-in-the-loop: positioned as an adjunct, not a replacement for clinician review.
3. Potential application
Cardiology departments in Vietnamese hospitals can use plaque and stenosis analysis to speed up CCTA reporting for chest pain patients. Health check centers can add calcium scoring to cardiovascular packages. Teleradiology groups can run the web tool across multi-site CT networks.
4. Benefits
Quantifies coronary plaque, stenosis and calcium from CCTA in one web tool. Works with CT images from any scanner, so no scanner replacement is needed. Has TGA listing (ARTG ID 347719) and a US FDA 510(k) clearance for the Salix Central USA product (K243038). Web delivery avoids local installation.
5. Market trends & opportunities
Coronary CT angiography is increasingly used as a first-line test for chest pain, which increases the need for software that quantifies plaque quickly. Vietnamese cardiology centers with CT capacity are building coronary imaging programs and may seek analysis tools that run on existing scanners.
6. Other information
Registered as Artrya Ltd, ACN 624 005 741, West Perth, Australia. Company announcements list the ASX FDA clearance notice on 31 March 2025 and a capital raising in February 2025. Salix Central USA is cleared in the US (K243038). Founding year is not stated on the pages fetched.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































